RNAC
Cartesian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.03
+2.16%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$7.80
From 52W high−24.17%
Volume211360.00
Market cap$242.95M
P/E (TTM)—
P/S (TTM)164.5x
Div yield—
Key dataSep 18, 2026
Open
$7.80
From 52W high
−24.17%
Volume
211360.00
Market cap
$242.95M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
P/E (TTM)
—
RSI (14)
31.9
MomentumView details →
1D Return
+2.16%
YTD Return
+8.74%
SummaryUpdated Jun 1, 2026
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) is a clinical-stage biopharmaceutical company that was incorporated in 2007 and is headquartered in Watertown, Massachusetts. The company operates under the business name Selecta Biosciences and focuses on developing innovative nanoparticle-based immunomodulatory drugs for treating and preventing human diseases. Originally founded as a biotechnology research company, Cartesian has evolved into a clinical-stage enterprise with multiple therapeutic programs spanning gene therapy, biologics, and autoimmune treatments, with several candidates advancing through various phases of clinical trials.
Similar companies
Latest newsMore news →
Cartesian Therapeutics reported Q2 2026 results with net income of $15.8 million and diluted EPS of $0.46, and cash and cash equivalents of $149.3 million at quarter end.46d agoCartesian Therapeutics entered into a credit facility with total potential non-dilutive funding of up to $150 million, with a first funded tranche of $50 million.46d ago